Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
Rhea-AI Summary
Ultragenyx Pharmaceutical (NASDAQ: RARE), a leading biopharmaceutical company specializing in rare and ultra-rare genetic diseases, has scheduled its first quarter 2025 financial results conference call.
The earnings call will take place on Tuesday, May 6, 2025, at 5:00 p.m. ET. During this call, the company will present its financial performance for the quarter ending March 31, 2025, along with a corporate update.
Investors and interested parties can access the live webcast through the company's investor relations website at https://ir.ultragenyx.com/events-presentations. A replay of the conference call will remain available for three months following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
On the day this news was published, RARE declined 0.03%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
(415) 475-6370
ir@ultragenyx.com
Media
Joey Fleury
(415) 946-1090
media@ultragenyx.com
FAQ
When is Ultragenyx (RARE) Q1 2025 earnings call?
How can I listen to Ultragenyx RARE Q1 2025 earnings call?
How long will Ultragenyx RARE Q1 2025 earnings call replay be available?
What will be discussed in Ultragenyx RARE May 6 earnings call?
What is Ultragenyx RARE's business focus?
